您的当前位置:首页 > 科研团队 > 研究方向二:成像示踪 > 主要参与人

姓名:肖非

职称: 研究员
电话: 0756-2528106
电子邮件: xiaof35@sysu.edu.cn
通讯地址: 珠海市香洲区梅华东路52号中山大学附属第五医院分子影像中心

学历和工作经历

中山大学附属第五医院副院长,中山大学医学院传染病教研室主任,附属第五医院感染病防治中心党支部书记,临床医学、病毒学双博士,博士后,研究员,主任医师,博士生导师。2002年毕业于华中科技大学同济医学院德语医学班(6年制),毕业后留校在附属同济医院感染科从事医教研工作,2008年获“Charcot”奖学金,先后在法国国家健康与医学研究院肝脏病和病毒学研究所(Inserm U1110)和美国斯坦福大学微生物和免疫系进行博士和博士后研究,2018年通过中山大学“百人计划”引进至中山大学附属第五医院。在Gastroenterology(封面文章)、Gut、Journal of Hepatology、Nature Communications、PLoS Pathogens、mBio、Emerging Infectious Diseases、Journal of Virology等国际知名期刊发表SCI论文40余篇,引用超过4000次,主持2项国家自然科学基金面上项目等8项科研项目。担任广东省预防医学会感染病分会常委,Frontiers in Medicine副主编。

研究方向

1. 人胚胎干细胞来源的或成体细胞来源的细胞模型和类器官模型构建

2. 应用CRISPR/Cas9筛选系统等工具研究病毒和宿主相互作用的相互关系和抗病毒免疫的机制

3. 病毒性肝炎、脂肪肝、肝细胞癌的发病机制和药物治疗靶点研究

4. 新型冠状病毒肺炎等新发突发传染病的发病机制和治疗新策略研究

承担科研项目情况

在研科研项目:

1. 国家自然科学基金面上项目,82172241,应用含免疫细胞的肺类器官研究新型冠状病毒肺炎“炎症风暴”的机制,2022/01-2025/12,项目负责人

2. 国家自然科学基金面上项目,81870411,激酶AAK1通过磷酸化AP-2调控乙型肝炎病毒感染的机制研究,2019/01-2022/12,项目负责人

3. 广东省自然科学基金,2019A151501038,HIF-2α激活PI3K/AKT损伤线粒体功能促进非酒精性脂肪肝相关性肝细胞癌进展的机制研究,2019/10-2022/09,项目负责人

4. 中山大学“百人计划”-中青年杰出人才,2017/11-2022/11,项目负责人

已完成科研项目:

1. 广东省科技计划项目,2019A030317017,应用脐带血干细胞构建兼具人源化免疫系统和肝脏的小鼠模型,2018/09-2021/09,项目负责人,结题

2. 珠海市“新型冠状病毒感染防治”应急科技攻关专项,ZH22036302200028PWC,新型冠状病毒感染引起消化道感染的机制及防治研究,2020/03-2020/12,结题

3. 中山大学高校基本业务费青年教师重点培育项目,18ykzd03,AAK1磷酸化激活AP分子调控HBV感染的机制研究,2018/01-2019/12,结题

4. 中山大学新型冠状病毒防控科技攻关应急专项项目,2020032308,防治新冠病毒感染引起消化道病变的临床研究,2020/03-2020/12,结题

5. 中山大学热带病防治研究教育部重点实验室开放课题,2018kfkt08, 阻断AAK1和GAK干预重症登革热的实验研究, 2018/08-2020/08,结题

代表性成果

近期代表性论文

1. Xiao F#, Tang M#, Zheng X#, Liu Y*, Li X*, Shan H*. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6): 1831-1833.e3

2. Xiao F, Tang M, Shan H. Reply to Letter to the Editor: Presence of SARS-Coronavirus-2 in the ileal mucosa: another evidence for infection of GI tract by this virus (GASTRO-D-20-01382). Gastroenterology. 2020; S0016-5085(20)35167-2

3. Xiao F#, Fofana I#, Thumann C, Alles R, Mailly L, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF*. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut. 2015; 64(3): 483-494

4. Xiao F, McKeating JA, Baumert TF*. A bile acid transporter as a candidate receptor for hepatitis B and D virus entry. Journal of Hepatology. 2013; 58(6): 1246-1248

5. Xiao F, Wang S, Barouch-Bentov R, Neveu G, Pu S, Beer M, Schor S, Kumar S, Nicolaescu V, Lindenbach BD, Randall G, Einav S.Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release. mBio. 2018; 9(2): e02233-17

6. Xiao F#, Fofana I#, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoël M, Bukh J, Patel AH, Zeisel MB, Baumert TF*. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathogens. 2014; 10: e1004128

7. Xiao F#, Sun J#, Xu Y#, Li F#, Huang X#, Li H, Zhao J, Huang J, Zhao J*. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerging Infectious Diseases. 2020; 26(8):1920-1922.

8. Zhu C#, Xiao F#, Hong J, Wang K, Fusco DN, Zhao L, Jeong SW, Brisac C, Chusri E, Schaefer EA, Zhao H, Peng LF, Lin W*, Chung RT*. EFTUD2 is a novel innate immune regulator restricting hepatitis C virus infection through the RIG-I/MDA5 pathway. Journal of Virology. 2015; 89(13): 6608-6618

9. Pu S#, Xiao F#, Schor S, Bekerman E, Zanini F, Barouch-Bentov R, Nagamine CM, Einav S*. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Research. 2018; 155: 67-75

10. Huang M#, Li M#, Xiao F#, Pang P#, Liang J#, Tang T#, Liu S, Chen B, Shu J, You Y, Li Y, Tang M, Zhou J, Jiang G, Xiang J, Hong W, He S, Wang Z, Feng J, Lin C, Ye Y, Wu Z, Li Y, Zhong B, Sun R, Hong Z, Liu J, Chen H, Wang X, Li Z, Pei D*, Tian L*, Xia J*, Jiang S*, Zhong N*, Shan H*, Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, National Science Review. 2020; 7(9): 1428–1436

11. Zhong H#, Wang Y#, Shi Z#, Zhang L#, Ren H#, He W#, Zhang Z#, Zhu A#, Zhao J#, Xiao F#, Yang F, Liang T, Ye F, Zhong B, Ruan S, Gan M, Zhu J, Li F, Li F, Wang D, Li J, Ren P, Zhu S, Yang H, Wang J, Kristiansen K, Tun HM, Chen W, Zhong N, Xu X*, Li YM*, Li J*, Zhao J*. Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. Cell Discovery. 2021;7(1):23

12. Kang S#, Yang M#, He S#, Wang X#, Chen X, Chen Y, Hong Z, Liu J, Jiang G, Chen Q, Zhou Z, Zhou Z, Huang Z, Huang X, He H, Zheng W, Liao HX*, Xiao F*, Shan H*, Chen S*. A SARS-CoV-2 antibody curbs viral nucleocapsid protein induced complement hyperactivation. Nature Communications. 2021; 12(1): 2697

13. Chen Y#, He R#, Han Z, Wu Y, Wang Q, Zhu X, Huang Z, Ye J, Tang Y, Huang H, Chen J, Shan H*, Xiao F*. Cooperation of ATF4 and CTCF promotes adipogenesis transcriptional regulation. Cell Biology and Toxicology. 2021; Online ahead of print

14. Xu Z#, Tang M#, Chen P#, Cai H# and Xiao F*.  SARS-CoV-2 gastrointestinal infection prolongs the time to recover from COVID-19. Frontiers in Medicine. 2021; 8:683551

15. Li Y, Zhu C, Wang F, Zhu T, Li J*, Liu S, Xiao F*. Expression of interferon effector gene SART1 correlates with interferon treatment response against hepatitis B infection. Mediators of Inflammation. 2016; 2016: 3894816

16. Fu L#, Fang Y#, Luo D#, Wang B#, Xiao X, Hu Y, Niu Y, Zheng W, Xu H, Yang X, Chan PSF, Xu Z, Chen P, He J, Zhu H, Tang H, Huang D, Hong Z, Ma X, Hao Y, Cai L, Yang J, Ye S, Yuan J, Chen Y, Xiao F*, Wang Z*, Zou H*. (2021). Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: Cross-sectional survey in five cities in China. BJPsych Open. 2021; 7(6): e191

17. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee C, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nature Biotechnology. 2015, 33(5): 549-554

18. Lupberger J#, Zeisel MB#, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF*. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine. 2011;17(5): 589-595

获奖及荣誉

入选国家重大人才工程

获批教育部“双带头人”工作室建设

湖北省“百人计划”

广东省杰出青年医学人才

广东省抗击新冠肺炎疫情先进个人

广东好医生

中山大学“百人计划”

珠海市“英才计划”
珠海好人(敬业奉献好人)